Evidence map›Paper›PMID 42182845›Full record

ArticleOpen forum infectious diseases2026

Real-World Outcomes of Chemiluminescence Immunoassay Implementation for

Eli Wilber, Marcos C Schechter, Paulina A Rebolledo, Sheetal Kandiah, Bruce Aldred, Yun F Wang, Susan M Ray

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eli WilberDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-8413-2681
Marcos C SchechterDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Paulina A RebolledoDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-9808-063X
Sheetal KandiahDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Bruce AldredDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0009-0008-3034-9947
Yun F WangGrady Health System, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-7286-4866
Susan M RayDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

Funding

Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Neel Rajnikant Gandhi, Jyothi Rengarajan · 2022 to 2026
$5.8M
NIAID NIH HHS P30 AI168386
6 · The paper itself

Abstract

Fully automated interferon gamma release assays based on chemiluminescence immunoassay promise more efficient testing for tuberculosis infection but increase rates of positive test results when compared with semiautomated assays. We report an increase in borderline-positive interferon gamma release assay results (87.8% relative increase; 95% CI, 31.1%-170.0%), which led to modifications in clinical care following chemiluminescence immunoassay implementation.

Identifiers

PMID42182845
PMCPMC13196865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.